Burkina Faso

The ORS and zinc: A policy and advocacy primer outlines the current global status of ORS and zinc uptake and key actions to increase their scale-up, as well as advocate and communicate about improving access and use.PATH, with funding from the United States Agency for International Development and the Bill and Melinda Gates Foundation, reviewed literature and existing data sources and carried out 37 key informant interviews with global- and country-level stakeholders from five countries: Burkina Faso, Ethiopia, Kenya, Nigeria, and Pakistan.The findings summarized in this primer include key actions to scaling ORS and zinc, strategies for successful implementation, and priority areas for investment to advance progress.

Dr. Zanma Michaël John Compaore, Mandela Washington Fellow from Burkina Faso, reflects on his time at PATH and how it will inform his career.

Nanopore–based sequencing platforms offer the potential for affordable malaria molecular surveillance in resource–limited settings to track and ultimately counteract emerging threats, such as drug resistance and diagnostic escape.With support from the Bill and Melinda Gates Foundation and building on the success of NOMADS, NOMADS 2 is continuing to strengthen and expand the use of nanopore sequencing for malaria genomic surveillance.This factsheet provides an overview of the NOMADS 2 project.

This report—the final report of the New Nets Project—presents the primary results of the New Nets Project pilot evaluations across 16 districts in Burkina Faso, Mozambique, Nigeria, and Rwanda. Emphasis is on the epidemiological impact outcomes, along with important contextual outcomes related to entomology, insecticide-treated net durability, and human behavior.

Policies that build strong primary health care systems are essential to advancing health equity— but they are complex and difficult to design. PATH created the PHC in Policies Tracker as a consolidated source of information to equip stakeholders including policymakers, advocates, implementers, and donors with information about existing policies that shape PHC systems. This new virtual public dashboard tool maps and analyzes data about national-level health policy documents relevant to primary health care (PHC) in 26 low- and middle- income countries—comparing content of these policies with recommendations laid out in key global-level guidance frameworks such as the WHO PHC Monitoring Framework and Indicators (MFI). The tracker aims to improve understanding of policies for PHC in LMICs, add to the global conversation about how to design robust policy for PHC, and help users identify high-impact opportunities for action toward better health for all. This brief provides an overview of the findings and key takeaways from the tracker project, as well as information about methodology and limitations. Access the tracker at bit.ly/PHC_policy_tracker

PATH’s Asset Tracker project provides information on the status of scale-up of key evidence-based interventions that improve maternal, newborn, and child health, and nutrition (MNCHN) outcomes, and save lives. The MNCHN Asset Tracker dashboards allow users to quickly and efficiently compare different indicators across or within countries. This guide is a how-to for reading, packaging, and presenting data from PATH’s MNCHN Asset Tracker to inform advocacy efforts.

Medical devices are critical for detecting and treating many serious health conditions facing mothers and newborns, including anemia, pre-eclampsia, and neonatal respiratory distress. They also have expensive and complex training and maintenance needs and are thus challenging to manage effectively in low resource settings. However, there is a lack of systematic, cross-country, and cross-device data outlining these challenges and evaluating current device access.PATH led the Market Dynamics for Medical Devices (MD4MD) project to address this need, quantifying device availability and diagnosing key barriers to access for five priority countries and seven priority maternal, newborn, and child health (MNCH) devices. This report aims to summarize key findings from this research and outline an investment agenda for improving access to these critical devices.

Drawing on four decades of advocacy experience, PATH aims to play a catalytic role in advancing the practice of advocacy in health through fostering knowledge sharing, connection and collaboration among health advocates and other stakeholders. This learning brief highlights key takeaways from a virtual conversation between civil society advocates and a policymaker from Kenya, Uganda, and Burkina Faso about experiences and lessons in engaging policymakers for agenda and priority setting around PHC systems and policy implementation at national and regional levels.

S'appuyant sur quatre décennies d'expérience en matière de plaidoyer, PATH entend jouer un rôle de catalyseur pour promouvoir la pratique du plaidoyer dans le domaine de la santé en favorisant les échanges de connaissances, la connexion et la collaboration entre les acteurs de plaidoyer pour la santé et les autres parties prenantes. Ce dossier d'apprentissage met en lumière les principaux enseignements d'une conversation virtuelle entre les acteurs de la société civile et un responsable politique du Kenya, de l'Ouganda et du Burkina Faso sur les expériences et les leçons tirées de l'engagement des responsables politiques dans la définition de l'agenda et des priorités concernant les systèmes de SSP (soins de santé primaire) et la mise en œuvre des politiques aux niveaux national et régional.

Shigella is the leading bacterial cause of childhood diarrhea, and infections can have long-term effects on growth and development. No licensed Shigella vaccines currently exist, but several promising candidates in development could become available in a few years. PATH conducted a series of studies to better understand the public health value of potential Shigella vaccines and help inform decisions by international agencies, funders, vaccine developers, and national policymakers. This included a multi-country feasibility and acceptability study with national stakeholders and healthcare providers in Burkina Faso, Ghana, Kenya, Nepal, and Vietnam to identify preferences and priorities for future Shigella vaccines. These briefs provide an overview of the results in each of the study countries.